ArriVent BioPharma (AVBP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 18, 2026, with voting open until June 17, 2026 at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by June 4, 2026.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of three directors: James Healy, John Hohneker, and Stuart Lutzker, all recommended by the board.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Provision for other business to be addressed as may properly come before the meeting.
Audit committee and external auditor matters
Proposal to ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm for the upcoming fiscal year.
Latest events from ArriVent BioPharma
- Virtual meeting to elect directors, ratify auditor, and review compensation and governance.AVBP
Proxy filing28 Apr 2026 - Pivotal NSCLC trials advanced, ADC pipeline expanded, and cash runway extends into 3Q 2027.AVBP
Q4 20255 Mar 2026 - Virtual annual meeting to elect directors and ratify auditor, with updated governance and compensation.AVBP
Proxy Filing2 Dec 2025 - Virtual meeting to elect two directors and ratify auditor, with board support for all proposals.AVBP
Proxy Filing2 Dec 2025 - Net loss increased on higher R&D spend; cash runway extends into mid-2027.AVBP
Q3 202510 Nov 2025 - Net loss rose on R&D growth, but strong cash reserves support ongoing clinical progress.AVBP
Q2 202511 Aug 2025 - Firmonertinib delivered high response rates and durable CNS benefit in EGFR PACC mutant NSCLC.AVBP
Study Update23 Jun 2025 - Strong clinical progress and $282.9M cash runway support operations into 2026.AVBP
Q3 202413 Jun 2025 - Net loss reached $39.3M as cash rose to $298.7M, funding pipeline progress into 2026.AVBP
Q2 202413 Jun 2025